Predictive Oncology Inc
NASDAQ:POAI
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.8150
  • TODAY'S CHANGE (%)
    0.0607 (8.0472%)
  • Bid / Lots
    0.8100/ 25
  • Ask / Lots
    0.8200/ 1
  • Open / Previous Close
    0.7579 / 0.7543
  • Day Range
    0.7520
    0.8548
  • 52 Week Range
    0.5500
    3.7600
  • Volume
    125,516

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 15, 2024

  • Nov 13, 2024

      Show headlines and story abstract

    • 7:15AM ET on Wednesday Nov 13, 2024 by MT Newswires
      Companies Mentioned: POAI
      07:15 AM EST, 11/13/2024 (MT Newswires) -- ...

    • 7:15AM ET on Wednesday Nov 13, 2024 by MT Newswires
      Companies Mentioned: POAI
      07:15 AM EST, 11/13/2024 (MT Newswires) -- ...

    • 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: POAI

      tim@lifesciadvisors.com
      PREDICTIVE ONCOLOGY INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, December 31, 2024 2023 -------------- ---------------- ASSETS Current assets: Cash and cash equivalents $ 3,078,955 $ 8,728,660 Accounts receivable 463,834 277,641 Inventories 504,380 480,803 Prepaid expense and other assets 442,513 512,078 Current assets of discontinued operations 77,726 79,249 ------------ ------------ Total current assets 4,567,408 10,078,431 Property and equipment, net 402,909 491,214 Intangibles, net 221,473 241,339 Lease right-of-use assets 2,203,935 2,598,091 Other long-term assets 102,509 105,509 Non-current assets of discontinued operations - 902,665 ------------ ------------ Total assets $ 7,498,234 $ 14,417,249 ============ ============ LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,141,922 $ 1,334,064 Note payable 195,776 150,408 Accrued expenses and other liabilities 1,517,242 1,542,948 Derivative liability 1 1,376 Contract liabilities 257,393 302,499 Lease liability 496,788 444,897 Current liabilities of discontinued operations 207,644 174,839 ------------ ------------ Total current liabilities 3,816,766 3,951,031 Other long-term liabilities 10,046 5,459 Lease liability -- net of current portion 1,704,453 2,130,977 Non-current liabilities of discontinued operations - 58,002 ------------ ------------ Total liabilities 5,531,265 6,145,469 ------------ ------------ Stockholders' equity: Preferred stock, 20,000,000 shares authorized inclusive of designated below Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 shares outstanding as of September 30, 2024, and December 31, 2023 792 792 Common stock, $.01 par value, 200,000,000 shares authorized, 6,666,993 and 4,062,853 shares outstanding as of September 30, 2024, and December 31, 2023, respectively 66,670 40,629 Additional paid-in capital 180,156,184 175,992,242 Accumulated deficit (178,256,677) (167,761,883) ------------ ------------ Total stockholders' equity 1,966,969 8,271,780 ------------ ------------ Total liabilities and stockholders' equity $ 7,498,234 $ 14,417,249 ============ ============ PREDICTIVE ONCOLOGY INC. CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, -------------------------- ------------------------------ 2024 2023 2024 2023 Revenue $ 345,686 $ 676,626 $ 1,012,232 $ 1,308,102 Cost of sales 196,919 97,868 535,511 367,461 ---------- ---------- ----------- ----------- Gross profit 148,767 578,758 476,721 940,641 Operating expenses: General and administrative expense 1,582,671 2,344,620 5,834,783 6,823,324 Operations expense 633,422 638,696 2,188,936 2,099,974 Sales and marketing expense 246,650 334,439 1,268,824 1,112,412 Total operating expenses 2,462,743 3,317,755 9,292,543 10,035,710 Total operating (loss) (2,313,976) (2,738,997) (8,815,822) (9,095,069) Other income 36,378 47,838 64,497 118,618 Other expense (5,822) (60,671) (9,393) (60,671) Gain on derivative instruments 7 3,463 1,375 11,724 ---------- ---------- ----------- ----------- Loss from continuing operations (2,283,413) (2,748,367) (8,759,343) (9,025,398) Loss from discontinued operations (811,277) (415,083) (1,735,451) (1,483,222) ---------- ---------- ----------- ----------- Net (loss) $(3,094,690) $(3,163,450) $(10,494,794) $(10,508,620) ========== ========== =========== =========== Loss per common share, basic and diluted: Loss from continuing operations (0.36) (0.68) (1.74) (2.26) Loss from discontinued operations (0.13) (0.10) (0.34) (0.37) ---------- ---------- ----------- ----------- Net (loss) per common share, basic and diluted $ (0.48) $ (0.78) $ (2.08) $ (2.63) ========== ========== =========== =========== Weighted average shares used in computation -- basic and diluted 6,396,221 4,031,356 5,046,227 3,998,887